CRISPR Therapeutics AG Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
CRISPR Therapeutics AG quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • CRISPR Therapeutics AG Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $23.7M, a 8.76% increase year-over-year.
  • CRISPR Therapeutics AG Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $81.5M, a 9.47% decline year-over-year.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2023 was $81M, a 17.3% decline from 2022.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2022 was $97.9M, a 4.34% decline from 2021.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2021 was $102M, a 55.1% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $81M -$16.9M -17.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 $97.9M -$4.44M -4.34% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 $102M +$36.4M +55.1% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 $66M +$16.5M +33.3% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $49.5M +$10.3M +26.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $39.3M +$18.6M +90.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 $20.6M +$9.79M +90.3% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 $10.8M +$7.16M +194% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
2015 $3.68M +$2.99M +430% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 $695K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.